Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Ottobock SE & Co. KGaA (OBCKF) vs. Competitors

2 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
OBCKFOttobock SE & Co. KGaA$8,536.90$3.29B―0.00%Strong BuyUnlock the OBCKF analyst price target with TipRanks PremiumOBCKFUnlock the OBCKF top-analyst price target with TipRanks Premium
DE:AFXCarl Zeiss MeditecEUR 34.44EUR 3.02B20.60-21.01%Moderate SellUnlock the DE:AFX analyst price target with TipRanks PremiumOBCKF vs DE:AFXUnlock the DE:AFX top-analyst price target with TipRanks Premium
DE:COPCompuGroup MedicalEUR 28.40EUR 1.50B43.4218.23%―Unlock the DE:COP analyst price target with TipRanks PremiumOBCKF vs DE:COPUnlock the DE:COP top-analyst price target with TipRanks Premium
DE:DRW3Draegerwerk AG & Co. KGaAEUR 111.00EUR 1.62B12.1262.28%Moderate BuyUnlock the DE:DRW3 analyst price target with TipRanks PremiumOBCKF vs DE:DRW3Unlock the DE:DRW3 top-analyst price target with TipRanks Premium
DE:EUZEckert & Ziegler Strahlen und MedizintechnikEUR 14.50EUR 864.77M17.41-6.75%Moderate BuyUnlock the DE:EUZ analyst price target with TipRanks PremiumOBCKF vs DE:EUZUnlock the DE:EUZ top-analyst price target with TipRanks Premium
DE:SBSSTRATEC BiomedicalEUR 26.75EUR 303.90M-653.7523.27%Moderate BuyUnlock the DE:SBS analyst price target with TipRanks PremiumOBCKF vs DE:SBSUnlock the DE:SBS top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
OBCKFOttobock SE & Co. KGaA8536.900.000.00%
DE:AFXCarl Zeiss Meditec34.44-8.22-19.27%
DE:COPCompuGroup Medical28.405.2622.71%
DE:DRW3Draegerwerk AG & Co. KGaA111.0042.5862.22%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik14.50-2.11-12.71%
DE:SBSSTRATEC Biomedical26.756.2130.23%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts